Comments on: Mondego Bio Initiates First-in-Human Study of MB‑388, an Oral Dual PTPN2/PTPN1 Inhibitor Designed to Overcome Resistance to Cancer Immunotherapy

Comments on: Mondego Bio Initiates First-in-Human Study of MB‑388, an Oral Dual PTPN2/PTPN1 Inhibitor Designed to Overcome Resistance to Cancer Immunotherapy https://www.mondegobio.com/2026/11/05/mondego-bio-initiates-first-in-human-study-of-mb-388-an-oral-dual-ptpn2-ptpn1-inhibitor-designed-to-overcome-resistance-to-cancer-immunotherapy/ Developing Breakthrough Cancer Immunotherapies Thu, 05 Nov 2026 08:58:25 +0000 hourly 1 https://wordpress.org/?v=7.0.3